Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 935-941

  Maliepaard, Marc ^a   Van Gastelen, Margoˆt A ^a   Tohgo, Akiko ^c   Hausheer, Frederick H ^d   Van Waardenburg, Robert C A M ^a   De Jong, Laurina A ^a   Pluim, Dick ^a   Beijnen, Jos H ^b   Schellens, Jan H M ^a,b  

^a Division of Experimental Therapy   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c DAIICHI SANKYO CO   (Japan)

^d BioNumerik Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DOXORUBICIN; ELACRIDAR; EXATECAN; FLUOROURACIL; GLYCOPROTEIN P; IRINOTECAN; KARENITECIN; LURTOTECAN; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACRIDINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CELL SURVIVAL; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOQUINOLINES; NEOPLASM PROTEINS; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 0034906472     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
2. Antitumor activity of DX-8951f: A new camptothecin derivative
3. Phase I and pharmacokinetic studies of DX-8951f in patients with advanced tumors: An overview
4. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
5. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients
6. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
7. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
8. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content
9. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody
10. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation
11. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin
12. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue
13. Relationship between P-glycoprotein, multidrug resistance-associated protein, and cellular accumulation of topoisomerase I inhibitors
14. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter
15. A multidrug resistance transporter from MCF-7 breast cancer cells
16. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
17. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
18. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells
19. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
20. Reversal of resistance by GF120918 in cell lines expressing the half-transporter, MXR
21. The mouse Bcrpl/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
22. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice
23. Karenitecins. New preclinical developments with BNP1350 a novel, potent highly lipophilic camptothecin
24. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice
25. The relationships between glutathione, glutathione-S-transferase, and cytotoxicity of platinum drugs and melphalan in eight ovarian carcinoma cell lines
26. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro
27. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms in human plasma
28. Reduced cellular accumulation of topotecan: A novel mechanism of resistance in a human ovarian cancer cell line
29. A rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein-dye binding
30. High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine
31. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
32. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
33. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes
34. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
35. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant
36. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6
37. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C
38. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein
39. Pharmacology of drugs that alter multidrug resistance in cancer
40. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier
41. Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells
42. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
43. Subcellular localization and distribution of the BCRP transporter in normal human tissues
44. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
45. Co-administration of cyclosporin enables oral therapy with paclitaxel